Overview
NICE is unable to make a recommendation on olaparib (Lynparza) for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy. This is because AstraZeneca did not provide an evidence submission.
Last reviewed: 2 February 2022
Next review: We will review this decision if the company decides to make a submission.